首页|期刊导航|中国食品药品监管|B类药品生产许可证持有人关键人员评价指标体系构建与实证研究

B类药品生产许可证持有人关键人员评价指标体系构建与实证研究OA

Construction and Empirical Research of Evaluation Indicator System for Key Personnel of Type B Certificate Holder

中文摘要英文摘要

目的:针对药品上市许可持有人制度下,B 证持有人管理和关键人员履职能力参差不齐、企业安全主体责任落实不到位的问题,构建一套科学、可量化的评价指标体系.方法:基于委托-代理模型、药品质量体系模型及能力素质模型,综合运用半结构化访谈法、德尔菲法及层次分析法,确立指标体系及权重,并选取25家 B 证持有人进行实证研究.结果:构建了一套包含3个模块(机构及人员构成、关键人员动态管理、关键人员履职能力),涵盖39个一级指标及 122个二级指标的量化评价体系.实证研究显示,样本企业在"机构及人员构成"等静态指标上表现尚可,但在"生产负责人""药物警戒负责人"的履职能力以及"质量受权人"的独立决策能力方面存在短板.结论:本研究将人员的检查由主观定性判断转化为客观量化评估,为监管部门实施精准化、风险导向监管提供了科学依据,也为企业自我优化与持续改进提供了指引,对保障企业落实质量安全主体责任具有重要意义.

Objective:This study aims to establish a scientific and quantifiable evaluation indicator system addressing the issues of uneven management and performance competency among key personnel,as well as inadequate implementation of corporate primary responsibility for drug safety among type B certificate holders under the drug marketing authorization holder system.Methods:Based on principal-agent theory,pharmaceutical quality system theory,and the competency model,a combination of semi-structured interviews,the Delphi method,and the analytic hierarchy process was employed to determine the indicator system and corresponding weights.An empirical study was conducted involving 25 type B certificate holders.Results:A quantitative evaluation system was constructed,consisting of three modules(institutional and personnel composition,dynamic management of key personnel,and performance competency of key personnel),covering 39 primary indicators and 122 secondary indicators.The empirical study revealed that sample enterprises performed adequately on static indicators such as"institutional and personnel composition,"but exhibited deficiencies in the performance competency of the head of production and the qualified person responsible for pharmacovigilance,as well as in the independent decision-making capacity of the qualified person responsible for release.Conclusion:This study transforms personnel inspection from subjective qualitative judgment into objective quantitative assessments,providing a scientific basis for regulatory authorities to implement targeted and risk-oriented supervision.It also offers guidance for enterprises in self-optimization and continuous improvement,and is of great significance in ensuring that enterprises fulfill their primary responsibility for quality and safety.

李玉基;林炳勇;岳攀;栾志霞;曲婷婷;刘冬;张付滨;靳海迎;李涛

山东省药品监督管理局山东省药品监督管理局山东省药品监督管理局山东省药品监督管理局山东省药品监督管理局山东省药品监督管理局山东省药品监督管理局山东省药品监督管理局审评核查济南分中心山东省药品监督管理局

医药卫生

药品上市许可持有人B证持有人指标体系德尔菲法层次分析法实证研究

marketing authorization holdertype B certificate holderindicator systemDelphi methodanalytic hierarchy processempirical study

《中国食品药品监管》 2026 (9)

28-39,12

2025年中国药品监督管理研究会课题(2025-Y-Y-002)

10.3969/j.issn.1673-5390.2026.09.003

评论